Fate Therapeutics IncFATE
Price$2.30Intrinsic value$2.138% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $6.5M-52.4% YoYTTM through 30 Jun 2026
Net Income -$126MTTM through 30 Jun 2026
Free Cash Flow -$105.7MTTM through 30 Jun 2026

Margins

Current
Operating Margin-2,237.9%
Net Margin-1,941.1%

Returns

-75.9%ROE
-47.8%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio5.79x
Net Debt-$205.1Mnet cash position
Cash & Equivalents$32.4M

Quality Metrics

Altman Z-Score-7.94
Piotroski F-Score2 / 9
FCF Margin-1,627.8%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $6.6M
Diluted EPS-$1.05TTM
'20'21'22'23'24'25
FY2025: $-1.15

Dividend

No dividend

Capital Allocation

Capex Intensity57.2%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.